Human papillomavirus vaccination: The ESGO–EFC position paper of the European society of Gynaecologic Oncology and the European Federation for colposcopy

Joura, Elmar A.; Kyrgiou, Maria; Bosch, F. Xavier; Kesić, Vesna; Niemenen, Pekka; Redman, C. W. E.; Gültekin, Murat

doi:10.1016/j.ejca.2019.04.032

Cited by 37 publications

(28 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…WHO recently launched the strategy to eliminate cervical cancer with the goals of achieving 90% HPV vaccination coverage, 70% screening coverage, and 90% access to treatment for cervical pre-cancer and cancer [2]. Many relevant societies worldwide including the Korean Society of Gynecologic Oncology have been scrambling to release their own recommendations for HPV vaccines [15][16][17][18]. Despite these consistent efforts of WHO and various academic societies, the HPV vaccination strategies of governments in Japan and Korea do not seem satisfactory.…”

Section: Conflict Of Interestmentioning

confidence: 99%

Time for enhancing government-led primary prevention of cervical cancer

et al. 2021

View full text Add to dashboard Cite

Cervical cancer is a preventable disease. Lei et al. [1] recently demonstrated using the Swedish nationwide registry that human papillomavirus (HPV) vaccines protected not only precancerous cervical lesions but also invasive cervical cancers. In this study, the risk of cervical cancer among women who had been vaccinated <17 years of age was 88% lower than the unvaccinated population. This effective vaccination results in a survival benefit when 'herd immunity' is achieved through high vaccination coverage in a population. One systematic review and meta-analysis by Drolet et al. [2] found that unvaccinated persons would indirectly benefit from HPV vaccination if vaccination coverage of girls and women in a population exceeds 50%. Vaccine coverage of the study of Lei et al. [1] in Sweden was 83.9% in the 2002 birth cohort and as high as 83.3%-97.7% in Australia where cervical cancer incidence continually declined over the years of vaccination [3,4]. This critical role of high vaccine coverage rates in reduction of cervical cancer incidence suggest that the HPV vaccination program must be scaled to national levels.The World Health Organization (WHO) reported countries with HPV vaccines in the National Immunization Program (NIP) (Fig. 1), which showed that HPV vaccine coverages of most Asian countries was very low [5]. Whereas 83.4% and 62.5% of 15-year-old girls in Malaysia and Korea completed HPV vaccinations in 2018, respectively, vaccine coverage in Indonesia, the Philippines and Singapore ranged from just 0.1% to 0.7%. In Thailand, 91% of 12,500 girls aged 11 years in Ayutthaya province received at least 2 doses of HPV vaccine within a pilot vaccination program from 2014 to 2016, with excellent safety and high acceptability. Thereafter, HPV vaccination gradually expanded to the national level in

show abstract

Section: Conflict Of Interestmentioning

confidence: 99%

Time for enhancing government-led primary prevention of cervical cancer

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Moreover, the European Society of Gynaecologic Oncology and the European Federation for Colposcopy published in 2019 a position paper on HPV vaccine in which they suggest offering vaccination, on individual basis, to women with HPV-related disease and prior local treatment [48].…”

Section: Relationship With Other Guidelinesmentioning

confidence: 99%

HPV vaccination in women treated for Cervical Intraepithelial Neoplasia grade 2 or 3: evidence-based recommendation from the Multisociety Italian Guidelines for cervical cancer prevention

Venturelli¹

2021

EJGO

View full text Add to dashboard Cite

Women treated for Cervical Intraepithelial Neoplasia (CIN) grade 2 or 3 are at increased risk of CIN and cervical cancer. Human Papillomavirus (HPV) vaccination is effective in preventing CIN in women who are not infected by HPV. Some studies suggested that vaccination may reduce the risk of CIN2 or 3 in women treated for CIN. A working group including all Italian scientific societies involved in tackling cervical cancer developed a recommendation on vaccination against HPV for women treated for CIN2 or CIN3. Data sources, methods of study selection: The group conducted a systematic review of the literature published from January 2006 to May 2019. Evidence on safety outcomes was retrieved by a recent Cochrane Review on vaccination in the general population. To develop the final recommendation, evidences were appraised and integrated by a Panel of Experts using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Evidence to Decision framework. Tabulation, integration and results: Six eligible studies were included. Four were RCTs and two were cohort studies, with different timing of vaccination. An additional study, published in October 2019, was taken into consideration after external review. A reduction of 70% CIN2+ in the treatment group was estimated; the vaccine was considered safe. Conclusion:The working group recommends the use of HPV vaccination in women treated for CIN2 or 3. The strong recommendation is based on large estimated desirable effects and trivial anticipated undesirable effects (moderate certainty of evidence), negligible costs and savings (no studies included), and a positive judgment in terms of feasibility, acceptability, and impact on equity.

show abstract

“…HPV vaccines have been steadily incorporated in primary prevention programs worldwide, with 100 out of 195 countries having implemented national HPV vaccination (HPVv) programs as of October 2019 [10]. The European Society of Gynecologic Oncology (ESGO) supports vaccination programs for children and young adolescents, with a catch-up program for young adults, if feasible, and also vaccination on an individual basis [11].…”

Section: Introductionmentioning

confidence: 99%